GV participated in tech apprenticeship platform Multiverse’s $220m series D round while Amgen, UCB, UPMC and Takeda helped genetics disease drug developer Code Biotherapeutics raise $75m.
Funding
US-headquartered, technology-focused apprenticeship provider Multiverse has received $220m in series D funding from investors including internet technology group Alphabet’s GV unit. StepStone Group, Lightspeed Venture Partners and General Catalyst co-led the round, which also featured Founders Circle Capital, Audacious Ventures, Bond, D1 Capital Partners and Index Ventures. The round valued the company at $1.7bn and brought its overall funding to more than $400m.
Fund
Brazil-based mining group Vale has formed a $100m corporate venturing arm dubbed Vale Ventures in…
